Yung‐Jue Bang
Yung‐Jue Bang publishes mostly in Oncology, Pulmonary and Respiratory Medicine and Molecular Biology, on topics such as Gastric Cancer Management and Outcomes, Colorectal Cancer Treatments and Studies and Lung Cancer Treatments and Mutations.
- World rank
- #91,896 of 7,710,434 ranked researchers
- Rank in South Korea
- #418 of 162,609
- Works
- 1,065
- Citations
- 69k
- Citations per work
- 64.7
What does Yung‐Jue Bang research?
Yung‐Jue Bang's work is mostly in Medicine (64%), Biochemistry, Genetics and Molecular Biology (14%).
Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.
The fields and subfields, with their numbers
- Health Sciences68264.0%
- Medicine68264.0%
- Everything else23021.6%
- Life Sciences15314.4%
- 1Oncology30% of their works
- 2Pulmonary and Respiratory Medicine21% of their works
- 3Molecular Biology11% of their works
- 4Surgery10% of their works
- 5Cancer Research4% of their works
- 6Pathology and Forensic Medicine3% of their works
Research topics
- Gastric Cancer Management and Outcomes
- Colorectal Cancer Treatments and Studies
- Lung Cancer Treatments and Mutations
- HER2/EGFR in Cancer Research
- Cancer Immunotherapy and Biomarkers
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Pancreatic and Hepatic Oncology Research
- Esophageal Cancer Research and Treatment
Which keywords describe Yung‐Jue Bang's research?
The keywords of their largest research topics: Chemotherapy, Endoscopic Resection, Gastric Cancer, Molecular Characterization, Tumor Microenvironment, Epidemiology, Cetuximab and KRAS Mutations.
- Esophageal Carcinoma
- Pancreatic Cancer
- Biliary Tract Cancer
- Immune Checkpoint Blockade
- Breast Cancer
- EGFR Mutations
- KRAS Mutations
- Epidemiology
- Molecular Characterization
- Endoscopic Resection
- Chemotherapy
- Gastric Cancer
- Tumor Microenvironment
- Cetuximab
- Neoadjuvant Therapy
- Targeted Therapy
- HER2
- PD-1 and PD-L1
- Cholangiocarcinoma
- Surgical Complications
- Preoperative Chemoradiotherapy
Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.
All 21 words, with their numbers
- Chemotherapy5734 topics
- Endoscopic Resection3162 topics
- Gastric Cancer2551 topic
- Molecular Characterization2551 topic
- Tumor Microenvironment1582 topics
- Epidemiology1442 topics
- Cetuximab1421 topic
- KRAS Mutations1421 topic
- Neoadjuvant Therapy1342 topics
- EGFR Mutations1091 topic
- Targeted Therapy1091 topic
- Breast Cancer1031 topic
- HER21031 topic
- Immune Checkpoint Blockade851 topic
- PD-1 and PD-L1851 topic
- Biliary Tract Cancer831 topic
- Cholangiocarcinoma831 topic
- Pancreatic Cancer731 topic
- Surgical Complications731 topic
- Esophageal Carcinoma611 topic
- Preoperative Chemoradiotherapy611 topic
Where does Yung‐Jue Bang work?
Yung‐Jue Bang's main affiliation in the publication record is Seoul National University, South Korea.
How many publications and citations does Yung‐Jue Bang have?
OpenAlex counts 1,065 works and 68,938 citations for Yung‐Jue Bang, an h-index of 106, ranking #91,896 of 7,710,434 researchers worldwide on the quality score.
Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.
Other researchers named Yung‐Jue Bang
Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.
Discussion
Ask a question or share a note about Yung‐Jue Bang. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.